Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation

NACompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
BradycardiaTachycardiaAtrial FibrillationValvular Heart Disease
Interventions
DRUG

continue warfarin through the procedure

The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.

DRUG

Hold warfarin

For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.

DRUG

Warfarin held with heparin transition.

For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.

Trial Locations (2)

21045

Howard County General Hospital, Columbia

21224

Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT00721136 - Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation | Biotech Hunter | Biotech Hunter